272 related articles for article (PubMed ID: 22531441)
1. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
Chung S; Quarmby V; Gao X; Ying Y; Lin L; Reed C; Fong C; Lau W; Qiu ZJ; Shen A; Vanderlaan M; Song A
MAbs; 2012; 4(3):326-40. PubMed ID: 22531441
[TBL] [Abstract][Full Text] [Related]
2. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
3. Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.
Liu SD; Chalouni C; Young JC; Junttila TT; Sliwkowski MX; Lowe JB
Cancer Immunol Res; 2015 Feb; 3(2):173-83. PubMed ID: 25387893
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
5. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
[TBL] [Abstract][Full Text] [Related]
6. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
7. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
8. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
9. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity.
Li C; Chong G; Zong G; Knorr DA; Bournazos S; Aytenfisu AH; Henry GK; Ravetch JV; MacKerell AD; Wang LX
J Am Chem Soc; 2021 May; 143(20):7828-7838. PubMed ID: 33977722
[TBL] [Abstract][Full Text] [Related]
10. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the role of afucosylated glycoforms on the
Kwiatkowski A; Co C; Kameoka S; Zhang A; Coughlin J; Cameron T; Chiao E; Bergelson S; Schmid Mason C
MAbs; 2020; 12(1):1803645. PubMed ID: 32812835
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
[TBL] [Abstract][Full Text] [Related]
13. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
[TBL] [Abstract][Full Text] [Related]
14. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
[TBL] [Abstract][Full Text] [Related]
15. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
[TBL] [Abstract][Full Text] [Related]
16. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
18. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans.
Tsukimura W; Kurogochi M; Mori M; Osumi K; Matsuda A; Takegawa K; Furukawa K; Shirai T
Biosci Biotechnol Biochem; 2017 Dec; 81(12):2353-2359. PubMed ID: 29090617
[TBL] [Abstract][Full Text] [Related]
19. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
[TBL] [Abstract][Full Text] [Related]
20. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
